ArticleEClinicalMedicine2023

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial.

Andrea Alemany et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.